Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Clin Cancer Res. 2015 Jan 21;21(7):1614–1620. doi: 10.1158/1078-0432.CCR-14-0327

Table 2.

Multivariate Analysis

Covariate Overall Survival Relapse Free Survival
Univariate HR p-value Multivariate HR p-value Univariate HR p-value Multivariate HR p-value
DNMT3A mut and stnd dose (vs. DNMT3A wt or DNMT3A mut and high dose) 1.71 0.014 1.90 0.006 1.47 0.070 1.69 0.017
DNMT3A mut (vs. DNMT3A wt) 1.21 0.331 ------ ------ 1.02 0.911 ------ ------
High dose (vs. stnd dose) 0.83 0.355 ------ ------ 0.83 0.339 ------ ------
Age ≥60 (vs. Age <60) 2.16 <0.001 2.62 <0.001 2.25 <0.001 2.10 <0.001
Intermediate Cytogenetics (vs. Favorable) 2.59 0.016 2.71 0.016 1.27 0.388 1.37 0.317
Poor Cytogenetics (vs. Favorable) 3.29 0.006 2.66 1.10 1.68 0.096 1.19 0.616
Unknown Cytogenetics (vs. Favorable) 2.55 0.0800 3.62 0.022 1.42 0.391 1.68 0.268
Female sex (vs. Male sex) 0.92 0.645 ------ ------ 0.93 0.656 ------ ------
FLT3-ITD (vs. no FLT3-ITD) 1.45 0.068 1.87 0.006 1.15 0.455 1.56 0.037
NPM1 mut (vs. NPM1 wt) 0.84 0.390 0.50 0.002 0.79 0.174 0.55 0.005
IDH1 mutated (vs. IDH1 wt) 0.91 0.792 ------ ------ 0.75 0.375 ------ ------
IDH2 mutated (vs. IDH2 wt) 0.93 0.782 ------ ------ 0.87 0.585 ------ ------
Allo tx (vs. no allo-tx) 0.46 <0.001 ------ ------ 0.73 0.072 ------ ------

Abbreviations: mut, mutant; vs, versus; wt, wildtype; stnd, standard; Allo tx, Allogeneic transplant; HR, hazard ratio